{"id":"nct:NCT02245737","kind":"trial","title":"An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease","authors":["AstraZeneca"],"author_count":1,"year":2014,"published":"2014-09-22","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT02245737","source_url":"https://clinicaltrials.gov/study/NCT02245737","archive_url":"https://space-kitty.com/papers/nct:NCT02245737","updated":"2019-12-03","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study is to assess the efficacy and safety of lanabecestat compared with placebo administered for 104 weeks in the treatment of early Alzheimer´s disease. The study will test the hypothesis that lanabecestat is a disease-modifying treatment for participants with early Alzheimer´s disease, defined as the continuum of participants with mild cognitive impairment (MCI) due to Alzheimer´s disease and participants diagnosed with mild dementia of the Alzheimer´s type, as measured by change from baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) score at week 104 in each of the 2 lanabecestat treatment groups compared with placebo.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Alzheimer´s Disease"],"details":{"acronym":"AMARANTH","status":"TERMINATED","phase":"PHASE2, PHASE3","study_type":"INTERVENTIONAL","enrollment":2218,"sponsor":"AstraZeneca","conditions":["Alzheimer´s Disease"],"interventions":["DRUG: Lanabecestat","DRUG: Placebo"],"start_date":"2014-09-30","start_date_type":"ACTUAL","primary_completion_date":"2018-10-04","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}